US equities |
TSLA $394.18 ▲+5.90% MU $886.62 ▲+1.03% META $631.53 ▼-1.73% SPCX $145.08 ▼-1.63% NVDA $214.56 ▲+1.71% AAPL $343.62 ▼-1.18% SNDK $1,239.76 ▲+0.14% INTC $86.83 ▼-0.16%
FinancialContent

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

4.340 -0.060 (-1.36%)
Delayed Quote Updated: 10:04 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Recap: Abeona Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Recap: Abeona Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
The 7 Most Undervalued Penny Stocks to Buy in October 2023 ↗
Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well. 
Via InvestorPlace
News headline image
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Biotech Blockbusters to Turn $5,000 Into $50,000 ↗
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace
News headline image
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Joins Rare Disease Company Coalition
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Reports First Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces New Employee Inducement Grants
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >